Showing results (11-20 of 15) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Lung Cancer (Amsterdam, Netherlands)|April 2, 2021
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulationKeunchil Park, Gee-Chen Chang, Giuseppe Curigliano, et al.Critical Care Medicine|December 30, 2008
Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stressNacira Sennoun, Sennoun Nacira, Ferhat Meziani, et al.Plos One|July 19, 2012
Increased microparticle production and impaired microvascular endothelial function in aldosterone-salt-treated rats: protective effects of polyphenolsNatalia López Andrés, Angela Tesse, Véronique Regnault, et al.Nature Communications|April 20, 2019
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapyJordi Bertran-Alamillo, Valérie Cattan, Marie Schoumacher, et al.Molecular Cancer Therapeutics|June 28, 2013
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumabMike F Burbridge, Céline J Bossard, Carine Saunier, et al.Pageof 2